<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: November 2, 2000
Date of earliest event reported: October 31, 2000
AVIRON
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
<TABLE>
<S> <C>
0-20815 77-0309686
(Commission File No.) (IRS Employer Identification No.)
</TABLE>
297 N. BERNARDO AVENUE
MOUNTAIN VIEW, CA 94043
(Address of principal executive offices and zip code)
Registrant's telephone number, including area code: (650) 919-6500
------------------------
<PAGE> 2
ITEM 5. OTHER EVENTS.
On October 31, 2000, Aviron announced that it had submitted to the U.S.
Food and Drug Administration a Biologics License Application for its
investigational intranasal influenza vaccine, FluMist(TM). See press release
attached hereto as Exhibit 99.1.
ITEM 7. EXHIBITS.
<TABLE>
<S> <C>
Exhibit 99.1 Press Release, dated October 31, 2000, entitled "Aviron
Submits Biologics License Application for FluMist(TM) ---
Innovative Nasal Mist Flu Vaccine to be Co-Promoted with
American Home Products Upon FDA Approval."
</TABLE>
2
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, hereunto duly authorized.
AVIRON
Dated: November 2, 2000 By: /s/ C. Boyd Clarke
------------------------
C. Boyd Clarke
President and Chief Executive Officer
3
<PAGE> 4
INDEX TO EXHIBITS
<TABLE>
<S> <C>
Exhibit 99.1 Press Release, dated October 31, 2000, entitled "Aviron
Submits Biologics License Application for FluMist(TM) ---
Innovative Nasal Mist Flu Vaccine to be Co-Promoted with
American Home Products Upon FDA Approval."
</TABLE>
4
